CJ Bioscience, Inc. (KOSDAQ:311690)

South Korea · Delayed Price · Currency is KRW

3,775.00

+45.00 (1.21%)

At close: Oct 2, 2026

Market Cap	49.32B -62.2%
Revenue (ttm)	3.68B +8.7%
Net Income	-22.33B
EPS	-1,708.88
Shares Out	13.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,703
Open	3,800.00
Previous Close	3,730.00
Day's Range	3,700.00 - 3,800.00
52-Week Range	3,060.00 - 10,200.00
Beta	0.54
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services

Founded 2009

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 311690

Full Company Profile

Financial Performance

In 2025, CJ Bioscience's revenue was 3.69 billion, an increase of 6.52% compared to the previous year's 3.47 billion. Losses were -24.00 billion, -26.90% less than in 2024.

Financial Statements